Melanoma Peptide Vaccines (MART1 Analog, gp100 and Survivin) With GM-CSF and Low-Dose IL-2 as Immune Adjuvants, A Pilot Study.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2017
At a glance
- Drugs Aldesleukin (Primary) ; Melanoma vaccine; Sargramostim
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 21 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 12 Sep 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.